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EAT and assessed correlations among the EAT and three other com-
monly used empathy tasks.
Methods: Patients (n=92) and healthy controls (n=42) matched for 
age and education, completed the EAT, the Interpersonal Reactivity 
Index, the Questionnaire of  Cognitive and Affective Empathy and the 
Faux Pas task. Differences between groups were analyzed and correla-
tions were calculated between empathy measurement instruments.
Results: The groups differed in EAT performance, with controls outper-
forming patients. A moderating effect was found for the emotional expres-
sivity of  the target: while both patients and controls scored low when 
judging targets with low expressivity, controls performed better than 
patients with more expressive targets. Though there were also group dif-
ferences on the cognitive and affective empathy questionnaires (with lower 
scores for patients in comparison to controls), EAT performance did not 
correlate with questionnaire scores. Reduced empathy performance did not 
seem to be part of  a generalized cognitive deficit, as differences between 
patients and controls on general cognition was not significant.
Discussion: Individuals with schizophrenia benefit less from the emotional 
expressivity of other people than controls, which contributes to their impaired 
empathic accuracy. The lack of correlation between the EAT and the question-
naires suggests a distinction between self-report empathy and actual empathy 
performance. To explore empathic difficulties in real life, it is important to use 
instruments that take the interpersonal perspective into account.
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Background: Impairment of insight is a prominent feature of schizophrenia and 
is associated with poor adherence and poor outcomes. While many studies have 
investigated the nature of insight impairment in schizophrenia, few have charted 
its course longitudinally. In this study we investigated changes in different com-
ponents of insight during the first 12 months of antipsychotic treatment.
Methods: The sample comprised 107 never or minimally treated patients with 
a first episode of schizophrenia, schizophreiform or schizoaffective disorder. 
They were treated according to a fixed protocol with flupenthixol decano-
ate. Insight was assessed with the self-rating Birchwood Insight Scale and the 
investigator rated global insight item of the PANSS scale.Psychopathology was 
assessed with the PANSS and CDSS. Cognitive performance was assessed with 
the MATRICS. We performed evaluations at baseline, month 6 and month 12. 
Linear mixed effects mixed models for repeated measures were conducted to 
assess changes over time, adjusting for age, gender and educational status.
Results: There were no significant changes in the BIS subscales of  symp-
tom awareness, awareness of  illness or total BIS score. The need for 
treatment subscale improved slightly (p=0.02) while the PANSS global 
insight improved considerably (p<0.0001). Degree of  insight impair-
ment was only weakly correlated with psychopathology and cognition
Discussion: Insight impairment is common in schizophrenia and displays 
trait-like rather than state-like features. These findings have important clini-
cal implications.
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Background: CSF abnormalities and a neuroinflammatory pathophysi-
ology have been discussed for affective and non-affective psychosis for 
more than 30-years. Recent studies pointed towards a specific pheno-
type of  autoimmune-antibody mediated psychosis, but evidence is still 
sparse. Especially CSF data investigating autoimmune antibodies in 
large-scale CSF cohorts of  affective and non-affective psychoses are 
lacking.
Methods: We analyzed a retrospective naturalistic cohort of 592 patients 
with A) schizophrenia-spectrum disorders (N = 330) or B) depressive dis-
orders (N = 262) who underwent a lumbar puncture as part of the clinical 
routine in the Department of Psychiatry and Psychotherapy at the Ludwig-
Maximilians University Munich between July 2012 and May 2017. We used 
a predefined systematic algorithm for the database search in the clinical 
documentation system and data was extracted by TO and AG. The study 
was approved by the local ethics committee.
Results: We identified 592 patients with standard CSF parameters. 
Schizophrenia spectrum patients did not differ from depressive patients 
with regard to the white blood cell count (cells/µl) (p  =  0.774) or albu-
min quotient (p  =  0.663). The general prevalence of oligoclonal bands 
did not differ between groups (schizophrenia: 37.0%, depression: 37.8%; 
p  =  0.838). However, schizophrenia patients showed higher frequencies 
for intrathecal oligoclonal bands (32% of all oligoclonal bands) com-
pared to depressive patients (19.1% of all oligoclonal bands. (p = 0.034). 
124 schizophrenia-spectrum patients (54 first-episode patients) received 
CSF analyses for neural antibodies. None of the patients showed pos-
itive CSF results in any of the tested autoimmune-encephalitis panel 
(NMDA(N=119), AMPA-1(N=114), AMPA-2(N=114), CASPR(N=111), 
LGI-1(N=110) and GABA-B(N=112)-Antibodies) in CSF. The results for 
the intracellular onconeuronal and synaptic antibodies were also negative 
(Amphyphysin(N=93), Yo(N=58), Hu(N=94), Ri(N=94), CV2(N=93), 
Ma1(N=93) and Ma2(N=93)-Antibodies). Three of these patients with 
negative CSF titers did have low-titer neuronal antibodies in serum: 
CASPR-2-AB: 1:10, CASPR-2-AB: 1:50, Yo-AB: low band-intensity. 36 
depression patients were also tested for autoimmune antibodies and again 
no positive reports could be identified in CSF.
Discussion: This is the first analyses of autoimmune antibodies in first-
episode and recurrent schizophrenia and depressive mood disorder show-
ing no positive CSF titers. However, schizophrenia patients have a higher 
prevalence of intrathecal oligoclonal bands compared to affective patients 
pointing towards more immunological disturbances in this population. The 
here presented analyses are exploratory and need to undergo confirmatory 
analyses and quality control.
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Background: Auditory verbal hallucinations are a major symptom in 
schizophrenia but also affect patients with other diagnoses and healthy peo-
ple without any pathology. This applies also to delusions and hallucinations 
of other sensory modalities. Since most questionnaires that assess halluci-
nations focus on one particular disorder, the Questionnaire for Psychotic 
Experiences (QPE) was created to provide an instrument that is applicable 
independently of clinical status.
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